医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production

2020年01月25日 AM04:23
このエントリーをはてなブックマークに追加


 

TAIZHOU, China

China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), announced today that it will be increasing its production of its entire TCM product line, in response to recent Chinese government pronouncements signaling a large expansion of the role and use of TCMPs in the Chinese health care system.

The initial directive, promulgated by the State Council of the People’s Republic of China, contained general priorities in medical and healthcare system reform. This was followed by guidelines issued by the State Council together with the Central Committee of the Communist Party of China, which specifically called for all community health service centers and township clinics in the country to offer TCM services by 2022, including TCM-based solutions for the prevention and treatment of, and rehabilitation from, illness and disease. The guidelines were later reinforced with an announcement by the State Council on October 26, 2019.

After reviewing the Chinese authorities’ guidelines, which further directed that existing TCM hospitals should increase their service capacity, China SXT has begun instituting plans to take advantage of the opportunity presented through an immediate ramp up in production of its entire TCM line, including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements.

Mr. Feng Zhou, Chief Executive Officer and Director of China SXT, commented, “These new guidelines have provided us with both the impetus and the reassurance we needed to embark on our next phase of expansion, as we move forward to our stated goal of becoming one of the world’s leading specialty pharmaceutical company in TCMPs,” adding that “equally important to us is that with the increase in production came improvements in our production systems and technologies, which we have been able to fund thus far through existing cashflows.”

About China SXT Pharmaceuticals, Inc.

Founded in 2005 and headquartered in Taizhou City, Jiangsu Province, China, China SXT Pharmaceuticals, Inc. is an innovative pharmaceutical company focusing on the research, development, manufacture, marketing and sales of traditional Chinese medicine pieces, which is a type of Traditional Chinese Medicine that has been processed to be ready for use. For more information, please visit www.sxtchina.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks and for these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005425/en/

CONTACT

For more information, please contact:

Feng Zhou, Chief Executive Officer

Email: fzhou@sxtchina.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seoul Viosys’ Violeds Modules Proven to Disinfect 99% of Airborne Viruses in a Recent Testing Result
  • Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
  • Kaye推出适用于冷链运输市场的Kaye® Log -80℃ 疫苗温度记录器,以满足COVID-19疫苗储存和运输的要求
  • Kaye® (ケイ)は、COVID-19ワクチンの輸送・保管のニーズに応えるためにKaye® ログ -80ワクチン温度ロガーを、コールドチェーン市場向けに導入(発売)します。
  • DNP的新型非接触式透明屏幕可通过手的动作进行操作